Core Viewpoint - Investors with substantial losses in Coupang, Inc. have until February 17, 2026, to file lead plaintiff applications in securities class action lawsuits due to alleged failures in disclosing material information during the Class Period from May 7, 2025, to December 16, 2025 [1][3]. Group 1: Legal Actions - The lawsuits against Coupang and certain executives are based on allegations of failing to disclose material information, which constitutes a violation of federal securities laws [3]. - The first-filed case is Barry v. Coupang, Inc., et al., No. 25-cv-10795, with a subsequent case, Lee v. Coupang, Inc., et al., No. 26-cv-00047, expanding the class period [5]. Group 2: Allegations - Allegations include inadequate cybersecurity protocols that allowed a former employee to access sensitive customer information for nearly six months without detection [4]. - The company is accused of being subjected to heightened regulatory and legal scrutiny due to the data breach, which was not reported in compliance with Securities and Exchange Commission rules [4]. - Public statements made by the defendants are claimed to be materially false and misleading throughout the Class Period [4]. Group 3: Legal Representation - Kahn Swick & Foti, LLC is a prominent boutique securities litigation law firm involved in these cases, ranked among the top 10 firms nationally based on total settlement value [5]. - The firm represents a variety of clients, including institutional and retail investors, seeking recoveries for investment losses due to corporate fraud or malfeasance [5].

Core Viewpoint - A securities fraud lawsuit has been filed against Agilon Health, Inc. (NYSE: AGL) following a significant drop in its stock price after the resignation of its CEO and the withdrawal of its financial guidance for 2025 [1][2]. Group 1: Company Developments - Agilon Health's shares fell over 25% in after-hours trading on August 4, 2025, due to the unexpected resignation of CEO Steven Sell and the withdrawal of the company's full-year 2025 financial guidance [2]. - The company cited unexpected medical cost pressures and downward adjustments to prior revenue estimates as reasons for these actions [2]. Group 2: Legal Allegations - The lawsuit alleges that Agilon Health recklessly issued guidance for 2025 that was unlikely to be achieved, given known industry challenges [3]. - It is claimed that Agilon materially overstated the financial benefits from strategic actions intended to mitigate risks, leading to misleading statements about its business and prospects [3]. Group 3: Investor Information - Investors who purchased Agilon Health common stock between February 26, 2025, and August 4, 2025, may be eligible to recover losses, regardless of whether they sold their shares [4]. - The deadline to seek appointment as lead plaintiff in the lawsuit is March 2, 2026, and a class has not yet been certified [5]. Group 4: Whistleblower Information - Individuals with non-public information about Agilon Health are encouraged to assist in the investigation or report to the SEC under the whistleblower program, with potential rewards of up to 30% of any successful recovery [6]. Group 5: Legal Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - A class action securities lawsuit has been filed against agilon health, inc. for alleged securities fraud affecting investors between February 26, 2025, and August 4, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements and concealed information regarding the company's 2025 guidance, which they allegedly knew was unattainable due to industry challenges [2] - It is alleged that defendants overstated the financial benefits from strategic actions taken by agilon to mitigate risks, leading to materially false and misleading statements about the company's business and prospects [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 2, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 20 years of experience [4]

Core Viewpoint - Varonis Systems, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between February 4, 2025, and October 28, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Varonis provided overly positive statements while concealing material adverse facts about its ability to convert its customer base to a SaaS model, leading to reduced annual recurring revenue (ARR) growth potential [2] - On October 28, 2025, Varonis reported third-quarter financial results that significantly missed ARR expectations and lowered its full-year guidance, attributing this to weaker-than-expected renewals and conversions in its subscription business [2] - Following the announcement, Varonis' stock price plummeted from $63.00 per share to $32.34 per share on October 29, 2025, marking a decline of approximately 48.67% in one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until March 9, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Group 1 - The law firm Kirby McInerney LLP is investigating potential claims against Navan, Inc. regarding possible violations of federal securities laws or unlawful business practices by the Company or its senior management [1] - Navan conducted its initial public offering on October 30, 2025, selling approximately 36.9 million shares at $25.00 per share [2] - In its third quarter fiscal 2026 financial results released on December 15, 2025, Navan reported a GAAP loss from operations of $79 million, compared to a loss of $19 million in the same period the previous year, indicating a significant decline in operational performance [2] - The GAAP operating margin for Navan was reported at (41%), a decrease from (13%) in the same period last year, highlighting worsening profitability [2] - Following the announcement of the CFO's immediate resignation and the associated financial benefits, Navan's share price fell by $1.74, or approximately 11.9%, closing at $12.90 on December 16, 2025 [2]

Core Points - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of CoreWeave, Inc. securities between March 28, 2025, and December 15, 2025, inclusive [1] - Investors who purchased CoreWeave securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A lead plaintiff must move the Court by March 13, 2026, to represent other class members in the litigation [3] Case Details - The lawsuit alleges that CoreWeave's defendants made false and misleading statements regarding the company's ability to meet customer demand and understated risks associated with reliance on a single third-party data center supplier [5] - The lawsuit claims that these misstatements were likely to have a material negative impact on CoreWeave's revenue, leading to investor damages when the truth was revealed [5] Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions, as Rosen Law Firm has achieved significant settlements for investors, including over $438 million in 2019 [4]

Core Viewpoint - A class action lawsuit has been filed against Coupang, Inc. regarding allegations of securities fraud and unlawful business practices related to a significant data breach affecting customer information [1][2]. Group 1: Lawsuit Details - The class action lawsuit is focused on whether Coupang and its officers/directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Coupang securities during the Class Period have until February 17, 2026, to request to be appointed as Lead Plaintiff [2]. Group 2: Data Breach Incident - On November 30, 2025, it was reported that Coupang experienced a data breach affecting 33.7 million customer accounts, leading to a stock price drop of $1.51 per share (5.36%) to close at $26.65 on December 1, 2025 [4]. - Following the breach, Coupang's CEO resigned, and a police raid occurred at Coupang's offices, resulting in a further stock price decline of $0.87 per share (3.2%) to close at $26.06 on December 10, 2025 [5]. - On December 16, 2025, Coupang acknowledged the breach in a filing with the U.S. Securities and Exchange Commission, revealing that a former employee may have accessed personal information of up to 33 million customers, causing the stock price to fall by $0.47 per share (2.03%) to close at $22.72 on December 17, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation, alleging securities fraud and unlawful business practices by the company and its officers [2]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP for participation in the class action, with a deadline to apply as Lead Plaintiff by February 09, 2026 [2]. - A copy of the complaint related to the lawsuit can be accessed through Pomerantz's website [2]. Group 2: Company Performance - On October 23, 2025, Integer revised its full-year 2025 guidance, projecting net sales growth between -2% to 2% and organic sales growth of 0% to 4% for 2026 [4]. - The company acknowledged that two of its electrophysiology devices faced slower than expected market adoption, which is anticipated to affect demand into 2026 [4]. - Following this announcement, Integer's stock price dropped by $35.22, a decline of 32.28%, closing at $73.89 per share on the same day [4].

Core Viewpoint - The U.S. Supreme Court has rejected Citigroup's appeal, requiring the bank to face a lawsuit alleging it orchestrated fraud that led to over $1 billion in losses for Oceanografia, a bankrupt oil services company in Mexico [1][5]. Group 1: Lawsuit Background - The lawsuit, initiated by over 30 plaintiffs including bondholders and shipping companies, has been ongoing for ten years and will continue following the Supreme Court's decision [1][5]. - Oceanografia provided drilling services for Pemex, Mexico's state oil company, and was taken over by the government in 2014 before declaring bankruptcy two years later [1][5]. Group 2: Allegations Against Citigroup - Plaintiffs accuse Citigroup's Banamex division of providing $3.3 billion in loans to Oceanografia between 2008 and 2014, despite knowing the company was heavily indebted and allegedly forging Pemex's signatures on authorization documents [1][5]. - Citigroup later discovered $430 million in fraudulent prepayments related to these loans [6]. Group 3: Court Findings - The Eleventh Circuit Court found sufficient evidence that Citigroup concealed critical information about Oceanografia while profiting from interest on the fraudulent prepayments [6]. - The court expressed skepticism regarding Citigroup's claim of ignorance about Oceanografia's actions, stating it was "incredible" for such an experienced bank to be unaware [2][6]. Group 4: Legal Arguments - Citigroup's appeal focused on the bondholders' claims, arguing they lacked the right to file a civil lawsuit under the RICO Act, which allows for triple damages in cases of racketeering [3][6]. - The bank contended that the Eleventh Circuit's ruling conflicted with decisions from three other federal appellate courts [4][6]. - Bondholders countered that the law was not intended to strip them of their rights to seek redress simply because other agencies might have pursued similar claims [4][7].

Core Viewpoint - A class action securities lawsuit has been filed against agilon health, inc. due to alleged securities fraud affecting investors between February 26, 2025, and August 4, 2025 [1][2] Group 1: Allegations - The lawsuit claims that defendants made false statements and concealed information regarding the company's guidance for 2025, which they knew was unrealistic given industry challenges [2] - It is alleged that defendants overstated the financial benefits from strategic actions taken by agilon to mitigate risks, leading to misleading statements about the company's business and prospects [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until March 2, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as a leading firm in securities litigation, with a team of over 70 employees [4] - The firm has been ranked in the Top 50 Report by ISS Securities Class Action Services for seven consecutive years, highlighting its expertise in complex securities cases [4]